• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Latin American diabetes therapeutics market to transform

Report: Latin American diabetes therapeutics market to transform

February 19, 2014
CenterWatch Staff

The Latin American diabetes therapeutics market will experience major changes within the next three years due to the launch of innovative drugs that include three long-acting insulins and four non-insulin treatments. Nevertheless, pharmaceutical companies should continue their research to develop treatments that can restore beta-cell function and thereby postpone or prevent disease progression—areas that even newer therapies do not address.

New analysis from Frost & Sullivan, Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market, expects the diabetes therapeutics market to grow, due to the rising prevalence of diabetes in the region. Improved awareness among patients on the importance of early diagnosis and treatment of diabetes will ensure steady market growth in the next five years. The research covers non-insulin and insulin therapeutics.

Currently, type 2 diabetic patients with metabolic syndrome need to separately administer drugs for each diabetes, arterial hypertension and hyperlipidemia. As a result, pharmaceutical companies are focusing on drugs that increase the administration period while controlling elevated glucose levels and normalizing the lipid profile.

"Pharmaceutical companies are looking to introduce into the Latin American market fixed-dose, single-tablet products that will offer a new treatment panorama for type 2 diabetes patients with metabolic syndrome disorder by reducing the daily intake of pills," said Lucila Rocca, a Frost & Sullivan healthcare industry analyst.

However, some Latin American governments are promoting the development of insulin by local companies at a cheaper price since the public system pays for the bulk of diabetes treatments. Thus, generics become an interesting option due to their low pricing. The products that are being developed and purchased are mostly human or animal insulins, which is a threat for multinationals since they generate maximum revenue from analog insulins.

"In this scenario, pharmaceutical companies need to formulate an appropriate pricing strategy and educate society on the therapeutic and administration benefits of analog insulins over human or animal products to boost the sale volumes of analog insulins in the public segment," said Rocca. "Pharmaceutical companies also should offer prophylatic therapies based on genetic disposition since the population with prediabetes in Latin America is estimated to be approximately three times the size of the diabetes population."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing